logo-loader
HealthPharma & Biotech
Dimerix Ltd

Dimerix receives cash injection from tax refund

Dimerix Limited has recently received an R&D tax refund.

dimerix-CEO-Kathy-Harrisson-757.png
The company’s lead clinical program is DMX 200

Dimerix (ASX:DXB) has received $421,549 cash as part of the federal government research and development tax incentive program.

The refund relates to eligible FY16 expenditure across Dimerix’s Receptor-HIT platform technology development program which is evaluating new therapeutic treatments.

Dimerix is a clinical stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay.

The company’s lead clinical program, DMX 200, is in Phase II clinical trials for chronic kidney disease and has been granted Orphan Drug Designation status in the U.S. for a medical condition called focal segmental glomerulosclerosis (FSGS).

The condition is a leading cause of kidney failure in adults.

Preliminary data has indicated improved clinical outcomes with chronic kidney disease by significantly reducing proteinuria in animal models.

An estimated US$ 2.6 billion is spent in the U.S. each year, mainly on late stage therapies due to lack of early stage treatment options.


DMX-200: path to registration for FSGS

Phase 2 study

- Part A: Interim - confirmed safety and signs of efficacy: (reporting July 2017); and
- Part B: Efficacy of optimal dose(s) using extended release tablet (commencing 2017).

Complete Extended release tablet formulation

- Pharmacokinetic (PK) study for comparison of current three times daily version with extended release formulation (2H 2017)

Phase 3 development for FSGS – FDA Pre-IND meeting outcomes

- FDA agreed development as an adjunct (not combination) therapy; and
- Primary endpoint discussions positive.


Outlook for next 12 months

DMX-200 Program
- Complete extended release formulation for propagermanium - 1H 2017;
- Report Phase 2 dose escalation (Part A) – July 2017;
- Open IND for PK study – mid 2017;
- PK Study for extended release tablet - 2H 2017; and
- Commence Phase 2 Part B – 2H 2017, using extended release formulation.

DMX-250 Program
- Further pre-clinical studies for nonalcoholic steatohepatitis (NASH) program.

Platform technology
- Potential indications include diabetic retinopathy, cancer fatigue and multiple sclerosis; and
- Research collaborations and assay licensing opportunities.
 

Find out more from Kathy Harrison at Proactive's CEO Sessions.

Click on city below to register by email

- Melbourne: Tuesday 11th April.
- Sydney: Wednesday 12th April.
- Email Pauline here.
- Call office on (02) 9280 0700.

Presenter list

- Intermin Resources (ASX:IRC): MD Jon Price
- Southern Gold (ASX:SAU): MD Simon Mitchell
- Proteomics International Laboratories (ASX:PIQ): MD Richard Lipscombe
- Dimerix (ASX:DXB): CEO Kathy Harrison

Quick facts: Dimerix Ltd

Price: $0.10

Market: ASX
Market Cap: $15.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Northern Minerals reveals talks with US government agencies,...

Northern Minerals Ltd (ASX:NTU) CEO George Bauk tells Proactive he recently met US government agencies, who he says wanted to get a better sense of the Australian company's progress with its dysprosium production, and its strategy going forward. Bauk is currently in New York meeting with...

17 hours, 47 minutes ago

3 min read